Rigel Pharmaceuticals is a biotechnology business based in the US. Rigel Pharmaceuticals shares (RIGL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $19.11 – a decrease of 2.35% over the previous week. Rigel Pharmaceuticals employs 162 staff and has a trailing 12-month revenue of around $179.3 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $19.11 |
|---|---|
| 52-week range | $7.48 - $29.82 |
| 50-day moving average | $19.25 |
| 200-day moving average | $17.46 |
| Wall St. target price | $33.67 |
| PE ratio | 18.9091 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.99 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $19.36 from 2025-05-02
| 1 week (2025-04-29) | -1.07% |
|---|---|
| 1 month (2025-04-07) | 13.62% |
| 3 months (2025-02-07) | -11.76% |
| 6 months (2024-11-07) | 25.39% |
| 1 year (2024-05-07) | 1,526.89% |
|---|---|
| 2 years (2023-05-05) | 64.07% |
| 3 years (2022-05-06) | 22.2 |
| 5 years (2020-05-06) | 6.96% |
Valuing Rigel Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Rigel Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Rigel Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Rigel Pharmaceuticals shares trade at around 19x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Rigel Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $26.4 million.
The EBITDA is a measure of a Rigel Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $179.3 million |
|---|---|
| Operating margin TTM | 28.92% |
| Gross profit TTM | $137.3 million |
| Return on assets TTM | 10.75% |
| Return on equity TTM | -699.05% |
| Profit margin | 9.75% |
| Book value | $0.19 |
| Market Capitalization | $334.5 million |
TTM: trailing 12 months
We're not expecting Rigel Pharmaceuticals to pay a dividend over the next 12 months.
Rigel Pharmaceuticals's shares were split on a 1:10 basis on 26 June 2024 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rigel Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Rigel Pharmaceuticals shares which in turn could have impacted Rigel Pharmaceuticals's share price.
Over the last 12 months, Rigel Pharmaceuticals's shares have ranged in value from as little as $7.4843 up to $29.82. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rigel Pharmaceuticals's is 1.317. This would suggest that Rigel Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Rigel Pharmaceuticals, Inc. , a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .